Eric H. Rubin
American Association For Cancer Research · 214 works · 10,434 citations · h-index 55
Top works
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- Drug development and clinical trials—the path to an approved cancer drug
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
- Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation
- PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)
- Epothilones: Mechanism of Action and Biologic Activity
- Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
- Case report of a toxic reaction from a combination of tryptophan and phenelzine
- Ionizing Radiation Stimulates a Grb2-mediated Association of the Stress-activated Protein Kinase with Phosphatidylinositol 3-Kinase
- Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
- Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
- Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation.
- A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
- Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
- Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53
- Identification of a Nucleolin Binding Site in Human Topoisomerase I
- Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide.
- Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin.